14 November 2022 – New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’s NTCD-M3 is leading play in this sector

Posted on by Kirsty Richardson
A new report highlights a fast growing market for Live Biotherapeutics, reaching $2.6bn by 2030.  Destiny Pharma’s NTCD-M3 preventing C. difficile infections is leading play in this sector.  For full report click below:-